Clinical Trial Update: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) [Phase 1]

View source ↗

Summary

An open-label Phase I safety trial of pembrolizumab for neurological post-acute sequelae of SARS-CoV-2 infection (PD1-PASC I) is described, with status not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Post-Acute COVID-19 Syndrome | Phase 1 | Status: NOT_YET_RECRUITING